IR208

DB05106InvestigationalVaccines

IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients.... IR208 is currently undergoing Phase II studies in a 200-patient trial.

Mechanism: Pharmacologically active on T cell receptor beta variable 6-5, T cell receptor beta variable 13, and T cell receptor beta variable 5-6
Curator reviewed
Primary indication: Investigated for use/treatment in multiple sclerosis.Curator reviewed
Code names: IR208

Resolves to

Targets

A0A0K0K1A5TRBV6-5A0A0A6YYD4TRBV13A0A599TRBV5-6

What you can answer from here — as of July 03, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with IR208, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account